British patients among first in world to receive Omvoh

The UK's National Institute for Health and Care Excellence (NICE) has recommended Omvoh (mirikizumab) for the treatment of eligible adults in England and Wales with moderately to severely active ulcerative colitis.

Omvoh has been recommended for use on the National Health Service (NHS) in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if a tumor necrosis factor alpha inhibitor has not worked, cannot be tolerated or is not suitable.

"The first IL-23p19 antagonist to be made available in the NHS for the treatment of adults with moderate to severe ulcerative colitis"The Eli Lilly (NYSE: LLY) product had earlier met the primary and key secondary endpoints in the Phase III, LUCENT-1 and LUCENT-2 trials. It won regulatory approval in the UK in June.